Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications. Inflammation and oxidative stress, characteristic in COPD, are likely contributors to the reduction in nitric oxide (NO) bioavailability and vascular endothelial dysfunction in COPD patients; however, this has yet to be determined. Thus, the overall objective of this proposal is to identify the role of NO bioavailability in contributing to vascular endothelial dysfunction in patients with COPD and to provide insight into the molecular mechanisms involved. Our central hypothesis is that inflammation and oxidative stress, both independently, contribute to the reduction in NO bioavailability and vascular endothelial dysfunction in patients with COPD.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Augusta University
• Collaborator: American Heart Association
• Treatments: Antioxidants; Nitric Oxide; Salicylates; Salicylsalicylic acid; Sodium Salicylate

Criteria

Inclusion Criteria:

• Patients with COPD (GOLD stages II-IV) and matched healthy controls

• Caucasian or African American

• Both men and women

• Current and former smokers

Exclusion Criteria:

• GOLD Stage I

• Clinical diagnosis of heart disease, hypertension, or metabolic disease

• Vasoactive medications (i.e. nitrates, beta-blockers, ACE inhibitors, Viagra, etc.)

• Pulmonary hypertension

• Hypothyroidism

• Hyper-homocysteinemia

• Interstitial lung disease

• Phenylketonuria

• Pregnancy

• Sleep apnea

• Anemia

• Raynod's phenomenon

• Gangrene of the digits

• History of low platelets or coagulopathies

• Aspirin sensitivity or allergy